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Summary. Nuclear retinoid receptors mediate retinoid 
effects in controlling cell growth, differentiation, 
apoptosis, and carcinogenesis. Altered expression or 
activity of these receptors could abolish the retinoid 
signal transduction pathway and be associated with 
human carcinogenesis.  In  s i tu  hybridization is  a 
powerful tool for analyzing gene expression in formalin- 
fixed, paraffin-embedded tissue sections, especially for 
newly cloned genes or when no antibodies are available. 
Detection of altered retinoid receptor expression using in 
situ hybridization in premalignant and malignant tissues 
has provided important information about the roles of 
these receptors in cancer development and the response 
of these tissues to retinoid treatment. Among these 
receptors, altered expression of retinoic acid receptor-B 
(RAR-B) has been mostly detected in human cancers, 
including those of the head and neck, lung, esophagus, 
mammary gland, pancreas, and cervix. RAR-B is thus 
currently used as a surrogate endpoint biomarker in 
different clinical prevention trials of various cancers. 
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lntroduction 
Retinoids, which are structural and functional 
analogs of vitamin A, are known to regulate various 
essential biological processes, e.g., vision, reproduction, 
metabolism, hematopoiesis, bone development, and 
pattern formation during embryogenesis (Lotan, 1980; 
Sporn et al., 1994). Pharmacologically, retinoids have 
been recognized as important factors in modulating cell 
growth, differentiation, and apoptosis and suppressing 
carcinogenesis in a broad range of tissue types (Lotan, 
1980; De Luca, 1991; Gudas, 1992; Harvat and Jetten, 
1999). Clinically, retinoids can reverse premalignant 
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lesions, inhibit the development of second primary 
tumors, and induce differentiation of acute 
promyelocytic leukemia (Huang et al., 1988; Sporn et 
al., 1994; Hong and Sporn, 1997, Lippman and Davies, 
1997). These findings led to the use of retinoids in both 
chemotherapy for and chemoprevention of human 
cancers; retinoids were approved by the U.S. Food and 
Drug Administration for the treatment of acute 
promyelocytic leukemia, Kaposi7s sarcoma,  and 
cutaneous T-cell lymphoma. 
The effects of retinoids are mediated mainly by two 
classes of nuclear retinoid receptors: retinoic acid 
receptors (RARs), which bind to all-trans retinoic acid 
(RA) and 9-cis RA with similar affinity, and retinoid X 
receptors (RXRs), which bind to 9-cis RA (Mangelsdorf 
et al., 1994; Chambon, 1996). These receptors are 
members of the steroid hormone receptor superfamily, 
and each one has three subtypes (a ,  0, and y) having 
distinct amino- and carboxy-terminal domains. The 
genes RAR-a, RAR-B, and RAR-y are localized at 
chromosomes 17q21, 3p24, and 12q13, respectively, 
while the genes RXR-a, RXR-B, and RXR-y have been 
mapped to chromosomes 9q34.3, 6p21.3, and 1q22-23, 
respectively (Mangelsdorf et al., 1994; Chambon, 1996). 
In addition, the three RARs exhibit a greater nucleotide 
sequence homology within a subtype across species than 
between subtypes within a species. This has led to the 
suggestion that the receptor subtypes have different 
functions, which have been evolutionarily conserved. In 
previous studies, in situ hybridization revealed that each 
subtype exhibited a different distribution in adult tissues 
as well as specific patterns of expression in developing 
mouse embryos (Dolle et al., 1989; Ruberte et al., 1990, 
1991; Xu and Lotan, 1999). In humans, RAR-a mRNA 
is normally expressed in most tissues; however, RAR-B 
expression is more limited, as it is prevalent in neural 
tissues but barely detectable in skin, while RAR-y is 
expressed predominantly in the skin (Mangelsdorf et al., 
1994; Chambon, 1996). Also, as a whole, RXRs are 
widely expressed in adult tissues. RXR-B expression is 
found in almost al1 tissues at similar levels, whereas 
RXR-a expression is abundant in the liver, kidney, 
spleen, and skin. In contrast, RXR-expression appears to 
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be rather restricted, occurring in abundance mostly in 
muscle and the brain (Mangelsdorf et al. ,  1994;  
Chambon, 1996). 
Because nuclear retinoid receptors are the proximate 
mediators of many effects of retinoids on gene 
expression (De Luca, 1991; Gudas, 1992; Lotan, 1996; 
Chambon, 1996; Piedrafita and Pfahl, 1999), it is 
plausible to assume that changes in the expression and 
function of these receptors may cause aberrations in the 
response of cells to RA and thereby alter both the 
regulation of cell growth and differentiation and the 
expression of the transformed phenotype (De Luca, 
1991;  Lotan, 1996; Piedrafita and Pfahl,  1999). 
Specifically, it has been demonstrated that altered 
expression of nuclear retinoid receptors is associated 
with the malignant transformation of human cells (de 
The, 1996).  RAR-a  expression, for  instance, is 
abnormally produced by chromosomal translocation 
during malignant transformation in human 
promyelocytic leukemia (de The et al., 1990). Also, 
RAR-B gene is rearranged in human hepatocellular 
carcinoma as a result of insertion of a hepatitis B virus 
sequence (de The et al., 1989). Severa1 studies have also 
shown that decreased or lost expression of RAR-y in 
skin cancers or premalignant lesions (Elder et al., 1991; 
Finzi et al., 1992). However, most common is the loss of 
RAR-B expression, which has been seen in a number of 
cancers (Xu and Lotan, 1999). 
In situ hybridization as a tool for detecting a gene 
expression pattern in tissue sections 
In situ hybridization is a very powerful method of 
detecting gene expression in tissue specimens, especially 
when there is no antibody available or when detecting 
expression of newly cloned genes (Xu and Lotan, 1998). 
In situ hybridization can identify gene expression pattern 
in tissues; in other words, it can be used to localize the 
cellular origin of mRNA in tissue sections. This is often 
the first step in understanding gene function in the study 
of developmental biology (Aibrecht et al., 1998). 
The principie underlying in situ hybridization is to 
anneal a labeled DNA or RNA probe to cellular mRNA 
in tissue sections or cells. In situ hybridization is very 
sensitive, in particular when antisense RNA probes are 
used. The procedure consists of four major steps: (A) 
tissue-section preparation, including tissue fixation, 
dehydration, embedding, and sectioning; (B) probe 
labeling; (C) annealing of the probe to cellular RNA 
(hybridization); and (D) visualization of the expression 
pattern (autoradiography or color reaction). 
The probes used in in situ hybridization experiments 
are labeled either with 3 5 [ ~ ]  NTP or a hapten 
(digoxigenin or biotin). In the first case, hybridization is 
detected using autoradiography, while in the second 
case, antibodies are used to visualize the hapten. 
Although radioactive probes have been used 
successfully, they have some disadvantages in the 
routine analysis of numerous specimens over a long 
period of time. For example, the generation of a 
sufficiently intense signal by autoradiography has been 
shown to take 14 days or longer, the resolution of the 
signal in individual cells is limited, and the probe has to 
be prepared often because of the decay of the 
radioactivity. These disadvantages can be overcome by 
the development of a nonradioactive labeling method, as 
using nonradioactive probes provides results in about 2 
days (Xu et al., 1994a). 
Essential to al1 in situ hybridization analyses is the 
use of controls that demonstrate probe specificity. A 
commonly accepted control is  the use of sense 
riboprobes. Hybridization of antisense and sense 
riboprobes in parallel experiments and under identical 
conditions is particularly important if a gene appears to 
be broadly expressed. Once hybridization and washing 
conditions are established, hybridization using the sense 
control may be omitted. However, when a new tissue or 
significantly different embryonic stage is examined, the 
use of sense controls is strongly recommended (Albrecht 
et al., 1998). 
Having established that the nonradioactive labeling 
technique provides a rapid but sensitive method of 
detecting RAR mRNA in formalin-fixed, paraffin- 
embedded tissue sections, we proceeded to analyze 
numerous specimens in a variety of tissues, which are 
described below (see Fig. 1). 
Detection of altered expression of nuclear retinoid 
receptors in head and neck squamous cell 
carcinoma (HNSCC) and its premalignant lesions 
To localize the expression of nuclear retinoid 
receptors in tissue sections, we used digoxigenin-labeled 
antisense riboprobes of RAR-a, -B, and -y and RXR-a, - 
B, and -y for in situ hybridization in histological sections 
of specimens obtained from both normal volunteers and 
HNSCC patients (Xu et al., 1994b). Al1 specimens 
obtained from normal volunteers expressed these 
receptors. Aso ,  similar levels of RAR-y, RXR-a, and 
RXR-B mRNA were detected in most of the adjacent 
normal, hyperplastic, dysplastic, and malignant tissues. 
Specifically, RAR-a mRNA was detected in 94% of 
adjacent normal and hyperplastic tissues, 87% of 
dysplastic tissues, and 77% of HNSCCs. In contrast, 
RAR-B mRNA was detected in about 70% of adjacent 
normal and hyperplastic tissues; its expression decreased 
further to 56% in dysplastic tissues and 35% in 
HNSCCs. The difference in RAR-B mRNA leve1 in 
HNSCCs and adjacent normal tissues was significant 
(Xu et al., 1994b). These results, together with cell-line 
data from other studies (Hu et al., 1991; McGregor et al., 
1997), indicated that decreased expression of RAR-B 
occurs in dysplastic tissues and may be associated with 
HNSCC development. 
Because RAR-í.3 expression was decreased in 
dysplastic lesion of the head and neck, we then analyzed 
tissue specimens of oral premalignant lesions obtained 
from patients who did not have cancer before and after a 
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3-month treatment using isotretinoin (Lotan et al., 1995). 
Al1 the normal tissue specimens expressed RAR-B 
mRNA. In contrast, RAR-B mRNA was detected in only 
21 of 52 oral premalignant lesions. The suppression of 
RAR-B mRNA expression in the lesions was significant 
(p<0.003). However, 35 of the 39 specimens available 
for evaluation after treatment expressed RAR-B mRNA 
(p<0.001). Additionally, al1 normal and premalignant 
specimens expressed similar levels of RAR-a, RAR-y, 
RXR-a, RXR-B, and RXR-y mRNA. The leve1 of RAR- 
B mRNA expression increased in the specimens obtained 
from 1 8  of 22 patients (82%) who had a response to 
isotretinoin and from 8 of the 17 (47%) patients who did 
not have a response (p=0.04). These results 
demonstrated that a selective loss of RAR-B mRNA 
expression occurs during the early stages of oral 
carcinogenesis but that this expression can be restored 
by isotretinoin treatment in humans. Furthermore, the 
RAR-g In normal RAR-$ sense RAR-g in N & T 
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I Flg. 1. In sEtu hybridization of formalin- fixed, paraffin-embedded tlssue sections obtained from normal and 
direnl cancers wiih 
RAR-O antisense probe. 
RXR-a m ANA was used 
as a control for intact 
RNA in the tissue 
sections. 
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association between the increase in RAR-B expression 
and clinical response suggests that RAR-B has a role in 
mediating retinoid response and may be a useful 
intermediate biomarker in trials of these agents in 
prevention of oral carcinogenesis (Lotan et al., 1995). 
Detection of altered expression of nuclear retinoid 
receptors in non-small cell lung cancer (NSCLC) 
Retinoids are required for the normal growth and 
differentiation of human bronchial epithelium (Jetten et 
al., 1992). They are also able to reverse growth of 
premalignant lesions (Hong and Sporn, 1997) and 
prevent second primary tumors in some NSCLC patients 
(Pastorino et al., 1993; Pastorino, 1995). Previous 
studies using northern blot analysis established that 
many lung cancer cell lines and primary tumors display 
abnormal RAR-B expression (Gebert et al., 1991; Houle 
et al., 1991, 1993). We extended these studies by using 
digoxigenin-labeled riboprobes for RAR-a, RAR-B, 
RAR-y, RXR-a ,  RXR-B, and RXR-y for in situ 
hybridization in histological specimens obtained from 79 
patients who had undergone pneumonectomy for 
NSCLC and, as a control, 17 patients having non-lung 
cancer (Xu et al., 1997a). Al1 79  samples from the 
NSCLC patients contained carcinomas; 3 6  also 
contained distant normal lung tissues, while 40  
contained adjacent normal tissues. Al1 receptors were 
expressed at very high levels in both control and distant 
normal specimens. However, in NSCLC, RAR-a, RXR- 
a ,  and RXR-y were expressed at very high levels, 
whereas RAR-y expression decreased to 74% in 
squamous cell  carcinoma (SCC) and 70% in 
adenocarcinoma (ADC), and RXR-B expression 
decreased to 73% in SCC and 78% in ADC. In contrast, 
RAR-B expression was detected in only 40% of NSCLC 
(p<0.0005). Together with previous cell-line studies 
(Gebert et al., 1991; Houle et al., 1991, 1993; Newi et 
al., 1991; Geradts et al., 1993; Berard et al., 1996), these 
data suggest that the loss of RAR-B expression may 
contribute to lung carcinogenesis, which was further 
confirmed by Picard et al. (1999). 
Next, we determined whether the expression of these 
receptors is modulated by chemopreventive intervention 
and analyzed the expression of RAR-B mRNA in 
bronchial biopsy samples obtained from heavy smokers 
at baseline and after 6 months of treatment using 
isotretinoin or placebo (Xu et al., 1999a). The results 
showed that RAR-B mRNA expression was lost in at 
least one of six biopsy specimens at baseline, in 30 of 
the 35 subjects (85.7%) in the isotretinoin group and in 
24 of the 33 subjects (72.7%) in the placebo group. After 
a 6-month treatment, the number of RAR-B-positive 
subjects in the isotretinoin group increased from 5 to 13 
(2.6-fold increase), meaning the percentage of cases 
having an aberrant RAR-B expression decreased to 
62.9% (22 of 35), which is a statistically significant 
decrease from the baseline expression leve1 (two-sided 
McNemar test, p=0.01). In the placebo group, there was 
no significant difference in RAR-B expression between 
that at baseline and that at 6 months. Also, RAR-B 
expression was not related to smoking status or reversal 
of squamous metaplasia. Ayoub et al. (1999) reached a 
similar conclusion, showing that RAR-B expression is 
frequently decreased in the bronchial epithelium of 
smokers and is upregulated at the end of isotretinoin 
treatment. 
Detection of altered expression of nuclear retinoid 
receptors in breast cancer 
Detection of altered expression of nuclear retinoid 
receptors in breast cancer was analyzed by both 
Widschwendter et al. (1997) and Xu et al. (1997b). In 
the first study, Widschwendter and colleagues 
demonstrated that RAR-a  was expressed in al1 
specimens, whereas RAR-y was expressed in al1 normal 
breast tissues but in only 11 of 14 tumors. In addition, 
RAR-B expression was found in al1 distant normal breast 
tissue specimens, but it was completely lost in 13 of 14 
tumors and morphologically adjacent normal tissue 
specimens. In the second study by Xu et al., the adjacent 
normal tissue specimens expressed al1 the nuclear 
retinoid receptors (RAR-a, RAR-B, RAR-y, and RXR-a) 
in nearly al1 cases. Expression of RAR-a, RAR-y, and 
RXR-a in ductal carcinoma in situ (DCIS) was similar 
to that in normal tissue; however, the expression of 
RAR-B was significantly lower in DCIS, especially in 
poorly differentiated DCIS. Also expression of RAR-y 
and RXR-a in invasive carcinoma was similar to that in 
DCIS and adjacent normal tissue specimens, whereas the 
expression of RAR-a and RAR-B decreased to 83.6% 
and 51.6%, respectively in invasive carcinoma. The 
decreased expression of RAR-a in invasive carcinoma 
compared with that in normal tissue as well as in DCIS 
was somewhat statistically insignificant, whereas the 
decrease in RAR-B expression compared with that in 
normal tissue as well as DCIS in was significant. 
Together with those of previous studies (Moon et al., 
1989; Swisshelm et al., 1994; Seewaldt et al., 1995, 
1997), these results clearly indicate a crucial role of 
RAR-B in the carcinogenesis of breast cancer. 
Detection of altered expression of nuclear retinoid 
receptors in esophageal cancer 
To study retinoid receptor expression in surgical 
specimens of esophageal cancer, we analyzed expression 
of RAR-B and RXR-a  mRNA in tissue specimens 
obtained from 157 esophageal cancer patients and of 
RAR-a and RAR-y mRNA in 40 of 157 specimens (Qiu 
et al., 1999). Of distant normal squamous mucosa (N = 
71) and distant columnar mucosa (N = 29) specimens 
that were also obtained from the 157 patients, 96% of 
the former expressed RAR-B. In contrast, RAR-B was 
expressed in only 84 of the 157 tumor specimens (54%). 
The difference in RAR-B expression between normal and 
tumor tissue specimens was statistically significant as 
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determined using the chi-squared test (pe0.0001). In 
addition, RAR-a, RAR-y, and RXR-a mRNA was 
expressed at very high percentages (92-98%) in both 
normal and tumor tissue specimens. Finally, RAR-B 
mRNA was expressed in 62% (26 of 42) of well- 
differentiated SCCs and 54% (27 of 50) of moderately 
differentiated SCCs, but only 29% (4 of 14) of poorly 
differentiated SCCs of the esophagus. These results 
indicate that decreased expression of RAR-B mRNA 
may be associated with the development of esophageal 
cancer. 
Our recent in vitro data demonstrated that the 
sensitivity of esophageal cancer cells to RA is associated 
with the expression and upregulation of RAR-B. 
Specifically, cell lines that do not express RAR-B are 
resistant to RA (Xu et al., 1999b). ?tivo recent clinical 
trials of 13-cis RA in patients having advanced 
esophageal cancer were unsuccessful, showing no 
response or progression of the disease (Slabber et al., 
1996; Enzinger et al., 1999). We propose that these 
failures may be due, at least in part, to loss of RAR-B 
expression. Furthermore, stable transfection of an RAR- 
B expression vector into an esophageal cancer cell line, 
which lacks RAR-B expression and inducibility by RA 
and is resistant to RA treatment, decreases cell growth 
and prolongs doubling time (our unpublished data). 
Detection of altered expression of nuclear retinoid 
receptors In pancreatic cancer 
Although RA was previously reported to inhibit the 
growth of a human pancreatic carcinoma cell line in 
culture (Rosewicz et al., 1995), we first used 
digoxigenin-labeled antisense riboprobes of RAR-a, 
RAR-B, RAR-y, and RXR-a for in situ hybridization in 
histological sections of 24 pancreatic carcinoma and 20 
adjacent normal tissue specimens (Xu et al., 1996a). Al1 
four receptors were detected in adjacent normal 
pancreatic tissue specimens; RAR-a, RAR-y, and RXR- 
a were also detected in al1 pancreatic carcinoma 
specimens. In contrast, RAR-B mRNA was detected in 
only 67% of the carcinoma specimens and when it is 
expressed, the level was lower than that in the 
corresponding adjacent normal tissues. RAR-B 
suppression was especially noted in moderately and 
poorly differentiated cancers. The selective suppression 
of RAR-B expression in certain pancreatic carcinomas in 
vivo may be associated with the development or 
progression of pancreatic cancer. 
Detectlon of altered expresslon of nuclear retlnold 
receptors In cervical cancer 
Expression of nuclear retinoid receptors in normal 
cervical tissues of experimental animals was first 
reported by Darwiche et al. (1994). In the mouse cervix, 
both ectocervical and endocervical epithelia have been 
reported to express RARs and RXRs at varying levels. 
For example, RAR-a, RAR-y, RXR-a, and RXR-B were 
associated with the cervical stratified squamous 
subjunctional epithelium. Also the columnar epithelium 
expressed high levels of RAR-a, RAR-B, RXR-a, and 
RXR-B mRNA, whereas RXR-y was undetectable in 
cervical epithelium using in situ hybridization (Darwiche 
et al., 1994). Additionally, RAR-B, RXR-a, and RXR-B 
mRNA was downmodulated in vitamin-A deficient mice. 
In surgical specimens obtained from cervical cancer 
patients, RARs were expressed in al1 adjacent normal 
cervical epithelia, but their expression was reduced in 
the lesions, which included cervical SCC and 
intraepithelial neoplasia 1, 11, and 111 (Xu et al., 1999c; 
our unpublished data). 
Detectlon of altered expression of nuclear retinoid 
receptors in skin cancer 
Severa1 studies have shown a decreased or lost 
expression of RAR-y in some skin cancers and 
premalignant lesions (Elder et al., 1991; Finzi et al., 
1992). In addition, in situ hybridization experiments 
using normal sun-exposed epidermis and adjacent SCC 
specimens have shown positive hybridization with 
antisense riboprobes for RAR-a and RAR-y but not 
RAR-B in normal epidermis (Xu et al., 1996b). 
Expression of RAR-a and RAR-y was not consistent 
throughout the epidermal layers, however, RAR-a and 
RAR-y receptor expression was much higher in the 
spinous and granular layers than in the basal layer. This 
pattern of expression was present in al1 normal skin 
samples examined. Also, specimens hybridized with 
antisense riboprobes for RXR-a, RXR-B, and RXR-y 
showed expression of al1 three receptors in normal 
epidermis. As with RAR-a and RAR-y, RXR-a, RXR-B, 
and RXR-y were expressed at higher levels in the 
spinous and granular layers of the epidermis than in the 
basal layer. 
Additionally, tissue sections from 17 skin SCCs 
were analyzed for the expression of nuclear retinoid 
receptors. In comparison with that in adjacent normal 
epidermis, SCC sections had a noticeable decrease in the 
expression of RAR-a, RAR-y, RXR-a, RXR-B and 
RXR-y. Again, RAR-B expression was not detected in 
any SCC cells. These results showed that RAR-a and 
RAR-y expression was decreased in 16 SCC cases (94%) 
and RXR-a, RXR-B, and RXR-y expression was 
decreased in 15 (88%), 12 (70%), and 14 (82%) SCC 
cases, respectively. Increased expression of these 
receptors was not found in any SCC sections examined. 
A low level of nuclear retinoid receptor expression 
was also seen in basal cell carcinoma (BCC) cases. Aii 
BCCs examined were found to express nuclear retinoid 
receptors at much lower levels than adjacent normal 
epidermis did (RAR-8 expression was not detected in 
any BCCs). However, because BCC cells are 
histologically similar to the nonkeratinizing basal cells 
of the epidermis, in situ staining of the tumor cells was 
compared with that of the epidermal basal layer. The 
majority of the BCCs expressed RAR-a, RAR-y, RXR- 
Detection of RAR using ISH 
a ,  RXR-B, and RXR-y at levels comparable with that in 
the basa1 cells of the epidermis. 
Detection of altered expression of nuclear retinoid 
receptors in prostate cancer 
In a recent study of nuclear retinoid receptor 
expression in the prostate, we first analyzed whether 
RARs and RXRs are differentially expressed in 8 normal 
human prostate tissue specimens and 10 prostate cancer 
tissue specimens and then determined whether oral 
fenretinide therapy impacts the expression of these 
receptors in 22 prostate cancers (Lotan et al., 2000). The 
data showed that RAR-a, RAR-y, RXR-a, and RXR-y 
mRNA was detected in most normal and malignant 
prostates. However, RAR-B mRNA expression was 
found in only 4 of 10  malignant prostates but was 
present in 7 of 8 normal prostates, which was 
statistically significant ( ~ ~ 0 . 0 5 ) .  Additionally, RXR-í3 
mRNA was expressed in 4 of 8 normal prostates but was 
not expressed in any of the malignant prostates 
(pc0.023). There were no differences in receptor 
expression between the fenretinide-treated group and a 
placebo group. Also, RAR-B and RXR-B mRNA 
expression was selectively lost in both prostate cancer 
and adjacent morphologically normal prostate tissue, 
supporting the concept of the field of carcinogenesis. 
One month of oral fenretinide administration (200 
mglday) did not influence the expression of retinoid 
receptors in prostate cancer. 
The use of RAR-B and RXR-í3 expression as a 
clinical marker for prostate cancer is premature and 
needs further investigation, but the finding of suppressed 
expression of RAR-B and RXR-B mRNA in 
histologically normal tissues adjacent to established 
cancer supports the concept of the field of cancerization, 
meaning that independent premalignant foci develop 
concurrently at various rates to form independent 
primary cancers in the same tissue. If the loss of RAR-B 
and RXR-í3 expression in normal prostates is proven to 
be a premalignant feature, its use as a surrogate clinical 
marker in prostate cancer chemoprevention studies may 
assume great importance. Because 50% of normal or 
RXR-B expression, i t  may be a more significant 
correlate. 
Use of RARs as biomarkers in clinical prevention 
trials 
RAR-O expression is suppressed selectively during 
the early stages of carcinogenesis in the oral cavity. 
Treatment of leukoplakia using 13-cis RA has been 
shown to cause a marked increase in the proportion of 
oral tissue specimens expressing RAR-B, which was 
associated with clinical response (Lotan et al., 1995). 
The same is partially true in bronchial epithelium 
specimens obtained from tobacco smokers (Ayoub et al., 
1999; Xu et al., 1999a). These findings have promoted 
the use of RAR-B as an intermediate biomarker because 
the leve1 of RAR-B expression decreases during the 
carcinogenic process and because it is upregulated by a 
chemopreventive agent (retinoid). Various clinical 
prevention trials of cancers of the head and neck, lung, 
skin, prostate, bladder, and breast are under way to 
further validate RARs as surrogate endpoint biomarkers. 
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